Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Finch Therapeutcs Grp Inc (FNCH)

Finch Therapeutcs Grp Inc (FNCH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 11,722
  • Shares Outstanding, K 1,606
  • Annual Sales, $ 107 K
  • Annual Income, $ -13,880 K
  • EBIT $ -18 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -8.82
  • Most Recent Earnings N/A on 05/10/24
  • Next Earnings Date 04/22/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.0000 +265.00%
on 03/23/26
13.3625 -45.37%
on 02/24/26
-5.5920 (-43.38%)
since 02/23/26
3-Month
2.0000 +265.00%
on 03/23/26
14.4000 -49.31%
on 01/16/26
-5.9500 (-44.91%)
since 12/23/25
52-Week
2.0000 +265.00%
on 03/23/26
16.1000 -54.66%
on 12/03/25
-6.7000 (-47.86%)
since 03/21/25

Most Recent Stories

More News
Finch Announces Delisting from Nasdaq and SEC Deregistration

FNCH : 7.3000 (-39.17%)
Finch Therapeutics to Participate in Upcoming June Investor Conferences

SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 7.3000 (-39.17%)
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

FDA lifted clinical hold on IND for CP101Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022$15 million drawn from...

FNCH : 7.3000 (-39.17%)
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 7.3000 (-39.17%)
Why Finch Therapeutics Stock Is Skyrocketing Today

The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.

FNCH : 7.3000 (-39.17%)
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 7.3000 (-39.17%)
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 7.3000 (-39.17%)

Business Summary

Finch Therapeutics Group Inc. is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery(R) platform to develop a novel class of orally administered biological drugs. The company's product candidate includes CP101, FIN-211, FIN-524 and FIN-525. Finch Therapeutics Group Inc....

See More

Key Turning Points

3rd Resistance Point 22.0500
2nd Resistance Point 16.9800
1st Resistance Point 12.1400
Last Price 7.3000
1st Support Level 2.2300
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 16.1000
Fibonacci 61.8% 10.7138
Fibonacci 50% 9.0500
Fibonacci 38.2% 7.3862
Last Price 7.3000
52-Week Low 2.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.